Results 241 to 250 of about 119,881 (373)

Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. [PDF]

Front Med (Lausanne)
Xie C, Shi L, Wei Z, Lai Y, Liu R.
europepmc   +1 more source

Fotoaferesi extracorporea come terapia di prima linea nel trattamento della GVHD cronica dopo trapianto allogenico di cellule staminali

, 2008
Andrea Tendas
openalex   +2 more sources

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) [PDF]

, 2018
Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke, Robert Zeiser   +7 more
openalex   +1 more source

Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug

HLA, Volume 107, Issue 1, January 2026.
ABSTRACT Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients.
Hannah C. M. Schenk, Ilse Gille, Carolt Arana, Jordi Rovira, Eduard Palou, Fritz Diekmann, Dave L. Roelen, Mirjam H. M. Heemskerk, Sebastiaan Heidt   +8 more
wiley   +1 more source

Abatacept today, TMA away: protecting the endothelium. [PDF]

Blood Adv
Ngwube A, Abraham A.
europepmc   +1 more source

Amustaline/glutathione pathogen‐reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial

Transfusion, Volume 66, Issue 1, Page 72-83, January 2026.
Abstract Background The ReCePI randomized, controlled trial compared amustaline/glutathione pathogen‐reduced (PR) and conventional red blood cell (RBC) transfusions in cardiac surgery. Study design and methods We performed a post‐hoc analysis of hemoglobin (Hb) utilization and safety outcomes.
Ian J. Welsby, Michael E. Sekela, Edward L. Snyder, James D. Gorham, John S. McNeil, Kathy Liu, Stanley Bentow, Thomas Gniadek, Laurence Corash, Nina Mufti, Richard J. Benjamin, for the ReCePI Study Group   +11 more
wiley   +1 more source

Association of donor and recipient single-nucleotide polymorphisms of interleukin-1 gene with outcomes after allogeneic hematopoietic stem cell transplantation in childhood. [PDF]

J Cancer Res Clin Oncol
Kämpfner K, Wittig S, Gruhn B.
europepmc   +1 more source

Therapy of Steroid-Refractory Chronic GVHD with Subcutaneous Low-Dose Alemtuzumab and Rituximab Combination Is Effective and Safe

, 2012
Cesar Homero Gutiérrez‐Aguirre, Olga Graciela Cantú‐Rodríguez, Óscar González‐Llano, José Carlos Jaime‐Pérez, Consuelo Mancías‐Guerra, Juan Antonio Flores‐Jiménez, Julio Alatorre‐Ricardo, David Gómez‐Almaguer   +7 more
openalex   +1 more source

Tissue tolerance: a distinct concept to control acute GVHD severity.

Blood, 2017
Shin-Rong Wu, P. Reddy
semanticscholar   +1 more source

Relapse of Acute Myeloid Leukemia With Concomitant Systemic Mastocytosis Five Years Post Allogenic Hematopoietic Stem Cell Transplantation

Case Reports in Hematology, Volume 2026, Issue 1, 2026.
Systemic mastocytosis (SM) with associated hematological neoplasia (SM‐AHN) is a rare and aggressive condition characterized by abnormal clonal proliferation of mast cells and the concurrent occurrence of hematologic malignancies, such as acute myeloid leukemia (AML).
Sona Vardanyan, Hilde K. Gjelberg, Lars Helgeland, Galina Tsykunova, Rakel Brendsdal Forthun, Håkon Reikvam, Stephen E. Langabeer   +6 more
wiley   +1 more source